Literature DB >> 26958276

Barriers and Facilitators to Patient-Provider Communication When Discussing Breast Cancer Risk to Aid in the Development of Decision Support Tools.

Haeseung Yi1, Tong Xiao1, Parijatham S Thomas2, Alejandra N Aguirre1, Cindy Smalletz1, Jill Dimond3, Joseph Finkelstein1, Katherine Infante1, Meghna Trivedi1, Raven David1, Jennifer Vargas1, Katherine D Crew1, Rita Kukafka1.   

Abstract

The purpose of this study was to identify barriers and facilitators to patient-provider communication when discussing breast cancer risk to aid in the development of decision support tools. Four patient focus groups (N=34) and eight provider focus groups (N=10) took place in Northern Manhattan. A qualitative analysis was conducted using Atlas.ti software. The coding yielded 62.3%-94.5% agreement. The results showed that 1) barriers are time constraints, lack of knowledge, low health literacy, and language barriers, and 2) facilitators are information needs, desire for personalization, and autonomy when communicating risk in patient-provider encounters. These results will inform the development of a patient-centered decision aid (RealRisks) and a provider-facing breast cancer risk navigation (BNAV) tool, which are designed to facilitate patient-provider risk communication and shared decision-making about breast cancer prevention strategies, such as chemoprevention.

Entities:  

Mesh:

Year:  2015        PMID: 26958276      PMCID: PMC4765687     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  17 in total

1.  Exemestane for breast-cancer prevention in postmenopausal women.

Authors:  Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson
Journal:  N Engl J Med       Date:  2011-06-04       Impact factor: 91.245

2.  The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention.

Authors:  Peter M Ravdin
Journal:  Cancer Prev Res (Phila)       Date:  2010-06

3.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

4.  Chemoprevention for breast cancer: overcoming barriers to treatment.

Authors:  Abenaa M Brewster; Nancy E Davidson; Worta McCaskill-Stevens
Journal:  Am Soc Clin Oncol Educ Book       Date:  2012

Review 5.  Rating the risk factors for breast cancer.

Authors:  S Eva Singletary
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

6.  Validation studies for models projecting the risk of invasive and total breast cancer incidence.

Authors:  J P Costantino; M H Gail; D Pee; S Anderson; C K Redmond; J Benichou; H S Wieand
Journal:  J Natl Cancer Inst       Date:  1999-09-15       Impact factor: 13.506

7.  Perception of breast cancer risk among women in breast center and primary care settings: correlation with age and family history of breast cancer.

Authors:  B L Smith; M A Gadd; C Lawler; D J MacDonald; S C Grudberg; F S Chi; K Carlson; A Comegno; W W Souba
Journal:  Surgery       Date:  1996-08       Impact factor: 3.982

Review 8.  Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.

Authors:  Heidi D Nelson; M E Beth Smith; Jessica C Griffin; Rongwei Fu
Journal:  Ann Intern Med       Date:  2013-04-16       Impact factor: 25.391

9.  American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

Authors:  Kala Visvanathan; Rowan T Chlebowski; Patricia Hurley; Nananda F Col; Mary Ropka; Deborah Collyar; Monica Morrow; Carolyn Runowicz; Kathleen I Pritchard; Karen Hagerty; Banu Arun; Judy Garber; Victor G Vogel; James L Wade; Powel Brown; Jack Cuzick; Barnett S Kramer; Scott M Lippman
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

Review 10.  Knowledge is not power for patients: a systematic review and thematic synthesis of patient-reported barriers and facilitators to shared decision making.

Authors:  Natalie Joseph-Williams; Glyn Elwyn; Adrian Edwards
Journal:  Patient Educ Couns       Date:  2013-11-09
View more
  15 in total

1.  Usability Testing of a Web-Based Decision Aid for Breast Cancer Risk Assessment Among Multi-Ethnic Women.

Authors:  Austin M Coe; William Ueng; Jennifer M Vargas; Raven David; Alejandro Vanegas; Katherine Infante; Meghna Trivedi; Haeseung Yi; Jill Dimond; Katherine D Crew; Rita Kukafka
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10

2.  Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.

Authors:  Meghna S Trivedi; Austin M Coe; Alejandro Vanegas; Rita Kukafka; Katherine D Crew
Journal:  Cancer Prev Res (Phila)       Date:  2017-06-13

3.  An Applied Framework in Support of Shared Decision Making about BRCA Genetic Testing.

Authors:  Thomas B Silverman; Gilad J Kuperman; Alejandro Vanegas; Margaret Sin; Jill Dimond; Katherine D Crew; Rita Kukafka
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

4.  Automatic Genetic Risk Assessment Calculation Using Breast Cancer Family History Data from the EHR compared to Self-Report.

Authors:  Margaret Sin; Julia E McGuinness; Meghna S Trivedi; Alejandro Vanegas; Thomas B Silverman; Katherine D Crew; Rita Kukafka
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

5.  Multiple approaches to enhancing cancer communication in the next decade: translating research into practice and policy.

Authors:  Claire C Conley; Amy K Otto; Glynnis A McDonnell; Kenneth P Tercyak
Journal:  Transl Behav Med       Date:  2021-11-30       Impact factor: 3.046

6.  Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries.

Authors:  Anne Brédart; Jean-Luc Kop; Antonis C Antoniou; Alex P Cunningham; Antoine De Pauw; Marc Tischkowitz; Hans Ehrencrona; Sylvie Dolbeault; Léonore Robieux; Kerstin Rhiem; Douglas F Easton; Peter Devilee; Dominique Stoppa-Lyonnet; Rita Schmutlzer
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

7.  Provider-patient communication about Zika during prenatal visits.

Authors:  Fangjian Guo; Alexander R Norton; Erika L Fuchs; Jacqueline M Hirth; Mariano A Garcia-Blanco; Abbey B Berenson
Journal:  Prev Med Rep       Date:  2017-05-18

Review 8.  Communication Needs of Cancer Patients and/or Caregivers: A Critical Literature Review.

Authors:  Jieyu Li; Xingjuan Luo; Qian Cao; Yi Lin; Yinghua Xu; Qiuping Li
Journal:  J Oncol       Date:  2020-05-07       Impact factor: 4.375

9.  Pilot study of decision support tools on breast cancer chemoprevention for high-risk women and healthcare providers in the primary care setting.

Authors:  Rita Kukafka; Jiaqi Fang; Alejandro Vanegas; Thomas Silverman; Katherine D Crew
Journal:  BMC Med Inform Decis Mak       Date:  2018-12-17       Impact factor: 2.796

10.  Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.

Authors:  Thomas B Silverman; Alejandro Vanegas; Awilda Marte; Jennie Mata; Margaret Sin; Juan Carlos Rodriguez Ramirez; Wei-Yann Tsai; Katherine D Crew; Rita Kukafka
Journal:  BMC Health Serv Res       Date:  2018-08-13       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.